Waiting
Login processing...

Trial ends in Request Full Access Tell Your Colleague About Jove

Neuroscience

Isolation and Direct Neuronal Reprogramming of Mouse Astrocytes

Published: July 7, 2022 doi: 10.3791/64175

Summary

Here we describe a detailed protocol to generate highly enriched cultures of astrocytes derived from different regions of the central nervous system of postnatal mice and their direct conversion into functional neurons by the forced expression of transcription factors.

Abstract

Direct neuronal reprogramming is a powerful approach to generate functional neurons from different starter cell populations without passing through multipotent intermediates. This technique not only holds great promises in the field of disease modeling, as it allows to convert, for example, fibroblasts for patients suffering neurodegenerative diseases into neurons, but also represents a promising alternative for cell-based replacement therapies. In this context, a major scientific breakthrough was the demonstration that differentiated non-neural cells within the central nervous system, such as astrocytes, could be converted into functional neurons in vitro. Since then, in vitro direct reprogramming of astrocytes into neurons has provided substantial insights into the molecular mechanisms underlying forced identity conversion and the hurdles that prevent efficient reprogramming. However, results from in vitro experiments performed in different labs are difficult to compare due to differences in the methods used to isolate, culture, and reprogram astrocytes. Here, we describe a detailed protocol to reliably isolate and culture astrocytes with high purity from different regions of the central nervous system of mice at postnatal ages via magnetic cell sorting. Furthermore, we provide protocols to reprogram cultured astrocytes into neurons via viral transduction or DNA transfection. This streamlined and standardized protocol can be used to investigate the molecular mechanisms underlying cell identity maintenance, the establishment of a new neuronal identity, as well as the generation of specific neuronal subtypes and their functional properties.

Introduction

The mammalian central nervous system (CNS) is highly complex, consisting of hundreds of different cell types, including a vast number of different neuronal subtypes1,2,3,4,5,6. Unlike other organs or tissues7,8,9, the mammalian CNS has a very limited regenerative capacity; neuronal loss following traumatic brain injury or neurodegeneration is irreversible and often results in motor and cognitive deficits10. Aiming to rescue brain functions, different strategies to replace lost neurons are under intense investigation11. Among them, direct reprogramming of somatic cells into functional neurons is emerging as a promising therapeutic approach12. Direct reprogramming, or transdifferentiation, is the process of converting one differentiated cell type into a new identity without passing through an intermediate proliferative or pluripotent state13,14,15,16. Pioneered by the identification of MyoD1 as a factor sufficient to convert fibroblasts into muscle cells17,18, this method has been successfully applied to reprogram several cell types into functional neurons19,20,21.

Astrocytes, the most abundant macroglia in the CNS22,23, are a particularly promising cell type for direct neuronal reprogramming for several reasons. First, they are widely and evenly distributed across the CNS, providing an abundant in loco source for new neurons. Second, astrocytes and neurons are developmentally closely related, as they share a common ancestor during embryonic development, the radial glial cells24. The common embryonic origin of the two cell types seems to facilitate neuronal conversion as compared to reprogramming of cells from different germ layers19,21. Furthermore, patterning information inherited by astrocytes through their radial glia origin is also maintained in adult astrocytes25,26,27, and seems to contribute to the generation of regionally appropriate neuronal subtypes28,29,30. Hence, investigating and understanding the conversion of astrocytes into neurons is an important part of achieving the full potential of this technique for cell-based replacement strategies.

The conversion of in vitro cultured astrocytes into neurons has led to several breakthroughs in the field of direct neuronal reprogramming, including: i) the identification of transcription factors sufficient to generate neurons from astrocytes15,19,31, ii) the unravelling of molecular mechanisms triggered by different reprogramming factors in the same cellular context32, and iii) highlighting the impact of developmental origin of the astrocytes on inducing different neuronal subtypes28,29,33. Furthermore, in vitro direct conversion of astrocytes unravelled several major hurdles that limit direct neuronal reprogramming34,35, such as increased reactive oxygen species (ROS) production34 and differences between the mitochondrial proteome of astrocytes and neurons35. Hence, these observations strongly support the use of primary cultures of astrocytes as a model for direct neuronal reprogramming to investigate several fundamental questions in biology12, related to cell identity maintenance, roadblocks preventing cell fate changes, as well as the role of metabolism in reprogramming.

Here we present a detailed protocol to isolate astrocytes from mice at postnatal (P) age with very high purity, as demonstrated by isolating astrocytes from the murine spinal cord29. We also provide protocols to reprogram astrocytes into neurons via viral transduction or DNA plasmid transfection. Reprogrammed cells can be analyzed at 7 days post-transduction (7 DPT) to assess various aspects, such as reprogramming efficiency and neuronal morphology, or can be maintained in culture for several weeks, to assess their maturation over time. Importantly, this protocol is not specific to spinal cord astrocytes and can be readily applied to isolate astrocytes from various other brain regions, including the cortical gray matter, midbrain, and cerebellum.

Subscription Required. Please recommend JoVE to your librarian.

Protocol

The following procedure follows the animal care guidelines of the Helmholtz Zentrum Munich in accordance with the directive 2010/63/EU on the protection of animals used for scientific purposes. Please make sure to comply with the animal care guidelines of the institution where the dissection is performed.

1. Preparation of dissection, dissociation, and culture materials

NOTE: Prepare all culture reagents within a biological safety cabinet and work using only autoclaved or sterile equipment. Dissection and dissociation reagents can be prepared outside of a biological safety cabinet.

  1. Prepare culture flasks by coating a T25 culture flask with poly-D-lysine (stock 1 mg/mL; working solution 20 µg/mL) in H2O for a minimum of 2 h. Afterwards, rinse 3x with H2O and air dry.
  2. Prepare dissection buffer by adding 5 mL of 1 M HEPES buffer solution to 500 mL of Hank's balanced salt solution (HBSS).
  3. Prepare one C-tube (see Table of Materials) per six spinal cords by adding 1950 µL of buffer X from the neural tissue dissociation kit (see Table of Materials). Store on ice during dissection. Prepare enzymatic digestion master mix by adding 20 µL of buffer Y and 10 µL of buffer A per C-tube (part of the neural tissue dissociation kit; see Table of Materials). Mix well and store at 4 °C until needed.
  4. Prepare 1x phosphate buffered saline (1x PBS) with calcium and magnesium and place on ice. Prepare basic culture medium by adding 5 mL of penicillin-streptomycin (final concentration, 100 U/mL), 5 mL of 45% D-glucose, and 5 mL of glutamine supplement (final concentration 2 mM; see Table of Materials) to 485 mL of DMEM/F12. Basic medium is stable at 4 °C for 4 weeks.
  5. Prepare astrocyte culture medium by adding 1 mL of B27-supplement and 5 mL of fetal bovine serum (FBS) to 44 mL of basic culture medium. Supplement medium with epidermal growth factor (EGF) and basic-fibroblast growth factor (bFGF) (10 ng/mL each). Add EGF and bFGF just before use to the appropriate amount of medium.
  6. For the dissection of spinal cord tissue, use a pair of large forceps with bent tip, a pair of small forceps with bent tip, one pair of small forceps, a pair of small scissors, and a small spatula.

2. Astrocyte isolation

  1. Isolate astrocytes from the spinal cord of postnatal mice for performing their direct reprogramming into functional neurons (Figure 1A). For this protocol, collect spinal cord tissue from mice at day 2-3 after birth. Collect six to eight spinal cords for astrocyte isolation. Use this same protocol to isolate astrocytes from other regions of the nervous system, such as the cortex, midbrain, and cerebellum. For these regions, obtain cells at five to seven days after birth.
    ​NOTE: When aiming to isolate astrocytes from regions that are not mentioned in this protocol, the age and input material should be experimentally determined.

3. Spinal cord tissue dissection

NOTE: Dissection of tissue can be performed outside of a biological safety cabinet.

  1. Sacrifice mice at P2-P3 by decapitation without anesthetizing the animal. Place the torso in a 35 mm Petri dish and keep on ice.
  2. Open the skin with scissors, remove vertebra with small scissors, extract the spinal cord, and place it in dissection buffer on ice. Under a stereotactic dissection microscope with 2x magnification, remove the meninges from the isolated spinal cords using forceps and transfer dissected and cleaned spinal cord tissue to a C-tube.

4. Magnetic activated cell sorting (MACS)

  1. Add 50 µL of enzyme P from the neural tissue dissociation kit (see Table of Materials) and 30 µL of previously prepared enzyme mix to each C-tube. Invert the C-tubes and place them on a heated dissociator (see Table of Materials), making sure that all tissue is collected in the lid of the tube.
  2. Run the 37_NTDK_1 dissociation program with a run time of approximately 22 min. Shortly before the end of the program, place a 70 µm strainer (see Table of Materials) on a number of 15 mL tubes equal to the number of C-tubes used and pre-wet the strainer with 2 mL of ice-cold PBS. Store 1x PBS on ice during the entire MACS procedure.
  3. After completion of the program, remove C-tubes and briefly centrifuge them to collect the tissue at the bottom of the tubes. Transfer the dissociated tissue from the C-tubes to the 15 mL tubes prepared by passing it through the strainer. Leave the strainer on 15 mL tubes.
  4. Rinse C-tube with 10 mL of 1x PBS to collect leftover tissue and collect it in the same 15 mL tube by passing through the strainer once more. Centrifuge the 15 mL tubes containing dissociated tissue at 300 x g for 10 min at room temperature.
    NOTE: Cool the centrifuge down to 4 °C after this step.
  5. Remove the supernatant without disturbing the cell pellet before resuspending the cells in 80 µL of 1x PBS; add 10 µL of blocking reagent from the mouse anti-ACSA-2 MicroBead kit (see Table of Materials). Gently mix by pipetting.
  6. Incubate at 4 °C for 10 min in the dark (fridge). Add 10 µL of anti-astrocyte cell surface antigen-2-coupled microbeads (see Table of Materials) and gently mix by pipetting. Incubate for 15 min at 4 °C in the dark.
  7. Wash cells by adding 3 mL of 1x PBS and centrifuge at 300 x g for 10 min at 4 °C. While centrifuging, assemble a magnetic separator (see Table of Materials) by placing the appropriate number of magnetic sorting columns (see Table of Materials) onto the separator with a 15 mL collection tube underneath. Rinse the columns with 500 µL of 1x PBS.
  8. Remove supernatant and resuspend the cells in 500 µL of 1x PBS before transferring the cell suspensions to the magnetic columns. Let drain by gravity. Wash the 15 mL tubes with 500 µL of 1x PBS and apply to column. Wash columns with 500 µL of 1x PBS for an additional two washes.
  9. Elute cells by removing the column from the separator, adding 800 µL of astrocyte culture medium and pushing cells out of the column with the included plunger.
  10. Plate cells in the previously prepared culture flasks by adding 4.2 mL of astrocyte culture medium supplemented with EGF and bFGF and culture at 37 °C and 5% CO2.
    NOTE: Coating culture flasks is not necessary for astrocytes isolated from other brain regions but provides a better substrate for astrocytes isolated from the spinal cord.
  11. Culture cells for approximately 7 days until confluency (80%-90%). If the cells are not confluent after 7 days, wait up until 10 days before plating them. After 10 days, cells do not proliferate anymore, and the reprogramming efficiency declines.

5. Seeding of astrocytes for reprogramming

NOTE: The following steps have to be performed under a biological safety cabinet with a safety level 1 (SL1).

  1. Prepare 24-well plates with poly-D-lysine coated glass coverslips in the same way culture flasks were prepared previously. To determine the number of plates needed, consider that astrocytes are plated at a density of 5-5.5 x 104 cells per well in a 24-well plate. Usually, isolating six spinal cords from P2 mice yields around 1 x 106 cells.
  2. Aspirate media from the T25 culture flasks containing the cultured astrocytes and wash once with 1x PBS. Detach the astrocytes from the culture flask by adding 0.5 mL of 0.05% Trypsin/EDTA and incubate at 37 °C for 5 min. Gently tap the side of the flask to release cells from the culture flask surface and check detachment under a brightfield microscope using a 10X magnification.
  3. Stop trypsinization with 2.5 mL of astrocyte culture medium and collect cell suspension in 15 mL tubes. Centrifuge at 300 x g for 5 min, aspirate supernatant, and resuspend cells in 1 mL of astrocyte culture medium. Calculate cell concentration using a haemocytometer or an automated cell counting system.
  4. Based on the number of cells, dilute the cell suspension with fresh astrocyte medium to obtain a solution of 1-1.1 x 105 cells per mL. Supplement the medium with EGF and bFGF at 10 ng/mL per factor. Add 500 µL of cell suspension, equivalent to 5-5.5 x 104 cells, to each well of the previously prepared 24-well plates and culture cells at 37 °C and 5% CO2.

6. Forced expression of transcription factors

NOTE: Before proceeding with the protocol, it is essential to properly design the experiment. In particular, it is important to always include a negative control for the reprogramming, namely a condition where no reprogramming factor is expressed. For instance, when using vectors carrying the cDNA for the reprogramming factor and a reporter (e.g., green fluorescent protein (GFP), DsRed), the negative control is represented by the same vector carrying only the reporter. When expressing multiple factors carrying different reporters, the negative control should be accordingly adjusted.

  1. The day after plating, inspect the 24-well plates to make sure cells have adhered to the coverslips.
  2. Based on the experimental aim and available resources, the forced expression of reprogramming factors can be achieved by viral transduction (see step 6.3) or DNA transfection (see step 6.4).
    NOTE: The use of retrovirus or lentivirus requires the approval of government authorities and must be performed under a biological safety cabinet within a laboratory with safety level 2 (SL2).
  3. Reprogram the astrocytes by transducing the cells with the retrovirus or lentivirus carrying the genetic information to express the reprogramming factor(s) of interest as described below.
    1. Transduce cells with a high virus titer of 1 x 1010-1 x 1012 particles/mL by adding 1 µL of the cell suspension directly to the astrocyte medium. This ensures a high infection rate. Culture the cells with the astrocyte medium containing viral particles at 37 °C for 24-36 h before proceeding with section 7 or section 8, depending on the purpose of the experiment.
      NOTE: Different promoters can be used to drive the expression of the transgenes (see also Representative Results). Constitutive promoters (e.g., CMV, CAG) induce the expression of the transgene earlier than inducible promoters; however, both types of promoter types have been successfully used to reprogram cells into neurons.
  4. DNA plasmids can also be introduced into astrocytes via DNA transfection as described below.
    NOTE: This can be done under a biological safety cabinet approved for SL1.
    1. Before transfection, obtain the transfection reagent, a plasmid DNA of the desired constructs, fresh astrocyte medium, and serum-reduced medium (see Table of Materials). Calculate the required amount of serum-reduced medium (see Table of Materials) by considering that each well of a 24-well plate requires 300 µL of serum-reduced medium. Add the appropriate amount of serum-reduced medium to a 50 mL tube and warm it to 37 °C.
    2. When the serum-reduced medium is warm, aspirate astrocyte medium from all wells and collect it in a 50 mL tube. Filter the collected astrocyte medium with a 0.45 µM syringe filter to remove detached cells.
    3. Add an equal volume of fresh astrocyte medium to the filtered medium to obtain a solution sufficient to add 1 mL of astrocyte medium per well. Maintain the astrocyte conditioned medium in the incubator at 37 °C until use (step 6.4.9).
      NOTE: The culture medium is re-used as it contains several secreted factors that support the viability of the culture.
    4. Add 300 µL of pre-warmed serum-reduced medium to each well and place the 24-well plate back to the incubator.
    5. Prepare solution A, consisting of DNA and serum-reduced medium. For each well, use a total of 0.6 µg of DNA and add it to 50 µL of serum-reduced medium. Store solution A at room temperature until use.
      NOTE: Typically, a technical triplicate per condition is considered. Therefore, a mix sufficient for 3.5 reaction is prepared (e.g., 2.1 µg of total DNA diluted in 175 µL of serum-reduced medium) to ensure enough material to transfect three wells of a 24-well plate.
    6. Prepare solution B, composed of the transfection reagent and serum-reduced medium. For each well, add 0.75 µL of transfection reagent to 50 µL of serum-reduced medium. As this solution is common to all transfection conditions, prepare it in bulk to reduce the variability across transfections.
    7. Incubate solution B at room temperature for 5 min. Add solution B to solution A drop by drop at a 1:1 ratio and gently mix. Do not vortex. Incubate solution A+B for 20-30 min at room temperature under the hood.
    8. Repeat step 6.4.5-6.4.7 for all transfection conditions. After 20-30 min, add solution A+B to each well drop by drop for a final volume of 100 µL. Gently shake the plate and place the cells back in the incubator at 37 °C for 4 h.
    9. After 4 h, remove the transfection medium and add 1 mL of the pre-warmed astrocyte conditioned medium prepared in step 6.4.3. Maintain cells for 36-48 h before proceeding with section 7 or section 8, depending on the purpose of the experiment.

7. Reprogramming of astrocytes (7 days analysis)

  1. Prepare neuronal differentiation medium by adding 1 mL of B27-supplement to 49 mL of basic culture medium (see step 1.4). After 24-48 h, depending on whether cells have been transduced or transfected (see steps 6.3 and 6.4, respectively), replace astrocyte medium with 1 mL of neuronal differentiation medium per well and culture cells at 37 °C and 9% CO2.
    NOTE: Cells can also be kept at 5% CO2 if no 9% CO2 incubator is available. However, neuronal reprogramming is more efficient under these conditions.
  2. Optional: To increase the reprogramming efficiency, supplement neuronal differentiation medium with Forskolin (final concentration of 30 µM) and Dorsomorphin (final concentration of 1 µM) when replacing the astrocyte medium to differentiation medium. When opting to treat cells with Forskolin and Dorsomorphin, provide a second dose of Dorsomorphin 2 days after the initial treatment. Add this second treatment directly to the culture medium.
  3. Direct reprogramming of murine astrocytes into neuronal cells normally occurs within 7 days after changing the medium. Hence, 7 days after the initiation of neuronal reprogramming, fix or collect cells for downstream analysis.

8. Reprogramming of astrocytes into mature neurons (long term cultures)

  1. Prepare neuronal differentiation medium by adding 1 mL of B27-supplement to 49 mL of basic culture medium (see step 1.4). After 24-48 h, depending on whether cells were transduced or transfected (see steps 6.3 and 6.4, respectively), replace astrocyte medium with 1 mL of neuronal differentiation medium supplemented with Forskolin (final concentration of 30 µM) and Dorsomorphin (final concentration of 1 µM) per well and culture cells at 37 °C and 9% CO2.
    NOTE: Cells can also be kept at 5% CO2 if no 9% CO2 incubator is available. However, neuronal reprogramming is more efficient under these conditions.
  2. Repeat Dorsomorphin treatment 2 days after the initial treatment by adding it directly to the neuronal differentiation medium.
  3. After 7 days from the start of neuronal reprogramming, prepare maturation medium by adding 6 µL of N2, 1.2 µL of NT3 (stock 20 µg/mL), 1.2 µL of BDNF (stock 20 µg/mL), 1.2 µL of GDNF (stock 20 µg/mL), and 1.2 µL of cAMP (stock 100 mM) to 189.2 µL of neuronal differentiation medium. Supplement neuronal differentiation medium present in each well with 200 µL of maturation medium.
    NOTE: Maturation medium is supplemented only for the first treatment. All subsequent treatments are done by partially replacing the neuronal differentiation medium as described below.
  4. Repeat the treatment with small molecules by removing 200 µL of neuronal differentiation medium and adding 200 µL of fresh maturation medium twice a week for up to 6 weeks. During the maturation, use cells for electrophysiological experiments (typically, at day 21 or later) or fix for downstream analysis (e.g., immunofluorescence).

Subscription Required. Please recommend JoVE to your librarian.

Representative Results

Primary cultures of astrocytes typically reach 80%-90% confluency between 7 to 10 days after MAC-sorting and plating (Figure 1B). Generally, a single T25 culture flask yields around 1-1.5 x 106 cells, which is sufficient for 20-30 coverslips when seeding cells at a density of 5-5.5 x 104 cells per well. The day after plating, cells typically cover 50%-60% of the coverslip surface (Figure 1C). At this stage, cultures consist almost exclusively of astrocytes, while other cell types, such as neuroblasts, are virtually absent (Figure 1D)29.

Reprogramming factors can be delivered to astrocytes either via retroviral or lentiviral transduction or through transfection of DNA plasmids. Usually, viral transduction infects more cells as compared to transfection. As direct neuronal conversion causes a substantial amount of cell death34,35, retroviral or lentiviral transduction is preferred to maximize the number of cells for analysis. Different promoters can be used to control the expression of the reprogramming factors: constitutive (e.g., CMV, CAG)15,32, inducible (e.g., Tet-responsive elements, Tet-ON)21, or cell type specific (e.g., GFAP promoter)36,37. When using constitutive or cell type specific promoters, astrocytes start to express detectable levels of the transgenes, assessed by fluorescent reporter expression (e.g., GFP, DsRed), within 24 h after the gene delivery, with each cell independent to the others. Conversely, inducible promoters allow to synchronize the expression of the transgenes across the cells transduced, as they are activated following the addition of a small molecule (e.g., doxycycline) to the culture medium. Detectable levels of the transcription factors are usually reached 18-20 h after the activation of the promoter. In most cases, the peak of the reprogramming factor expression is reached at around 48 h, with lentivirus-mediated expression taking slightly longer.

While transcriptional changes following reprogramming factors expression can be detected as early as 4 h32, robust changes occur after 24 h and later29,32. Morphological changes follow transcriptional changes, and first signs of conversion can be observed around 3 days post-transduction/transfection (3 DPT). At 7 DPT, induced neuronal cells are clearly distinguishable from astrocytes: their soma is smaller than control or un-reprogrammed astrocytes, they have long processes, and they are positive for neuronal marker βIII-tub and are negative for astrocyte marker GFAP (Figure 1E). However, it is worth noting that some cells can be either positive for both GFAP and βIII-tub, suggesting that the neuronal program has been induced but the astrocyte identity has not been inhibited, or negative for both markers, indicating the repression of the astrocyte identity but the absence of induction of the neuronal cascade. In either case, the cells usually maintain an astrocyte morphology.

For more functional analyses, such as electrophysiology or the evaluation of the generated neuronal subtypes, cultures are generally maintained for a minimum of 21 DPT and treated with maturation medium. At 21 DPT, many induced neurons are capable of firing action potentials and are positive for the mature neuronal marker NeuN as well as for the pan-synaptic protein Synaptophysin29 (Figure 1F).

Figure 1
Figure 1: Overview of astrocyte culture and reprogramming. (A)Timeline of astrocyte-to-neuron direct conversion. Each black line represents an important step in the protocol. (B) Representative brightfield images of cultured spinal cord-derived astrocytes after 7 days in culture. Pictures were taken using a brightfield microscope and 10x objective. Scale bar represents 100 µm. (C) Representative brightfield images of spinal cord astrocytes 1 day after re-plating at a density of 5.5 x 104 cells per well in a 24-well plate. Images were taken using a brightfield microscope and a 10x objective. Scale bar represents 100 µm. (D) Immunofluorescence image of a βIII-tub, Sox9, GFAP triple staining on astrocytes fixed 1 day after plating to demonstrate culture purity. Cells were fixed in 4% paraformaldehyde for 10 min and washed twice with 1x PBS. Cells were blocked using a 3% BSA, 0.5% Triton-X 100 in 1x PBS solution. Primary antibodies were diluted at the proper concentration (e.g., anti-GFAP 1:250; anti-βIII-tub 1:250; anti-Syp1 1:500) in blocking solution and incubated for 2 h at room temperature. Cells were washed three times with 1x PBS and incubated with fluorophore-conjugated secondary antibodies for 1 h at room temperature. Coverslips were washed three times with 1x PBS before mounting with Aqua Poly/Mount. Images were acquired using an epifluorescence microscope and a 40x objective. Scale bar represents 20 µm. (E) Immunofluorescence image of a βIII-tub, DsRed double staining to demonstrate astrocyte to neuron conversion with Ascl1 after 7 DPT. Protocol of immunofluorescence and image acquisition was as described above. Scale bar represents 20 µm. (F) Immunofluorescence images of a βIII-tub, DsRed, Synaptophysin 1 (Syp1) triple staining to demonstrate neuronal maturity after 21 DPT of reprogramming with Ascl1. Protocol of immunofluorescence and image acquisition was as described above. Scale bar represents 20 µm. Please click here to view a larger version of this figure.

Subscription Required. Please recommend JoVE to your librarian.

Discussion

Primary cultures of murine astrocytes are a remarkable in vitro model system to study direct neuronal reprogramming. In fact, despite being isolated at a postnatal stage, cells express typical astrocyte markers29, retain the expression of patterning genes28,29, and maintain the capacity to proliferate, similar to in vivo astrocytes at a comparable age38. After MACS-mediated isolation, cells first adhere to the flask and then start to proliferate, giving rise to highly enriched astrocyte cultures29. Importantly, cultured astrocytes do not dedifferentiate into a multipotent cell state nor get immortalized. Furthermore, they do not spontaneously generate neurons following the expression of a reporter protein (e.g., DsRed or GFP), but maintain an astrocyte identity. Also, they do not proliferate indefinitely, but rather slow down their proliferation and transition into a more mature stage, which reduces their direct neuronal reprogramming potential32,39.

There are several critical steps in this protocol: first, it is essential to carefully isolate the region of interest and remove any contaminating tissues. For example, to prepare spinal cord astrocytes, the spinal cord is extracted from the vertebrae and the dorsal root ganglia (DRG) are carefully removed. Second, converting cells undergo significant cell death34, which has a negative impact on the transduced cells and the overall culture, due to the stimulation of phagocytosis by surrounding astrocytes as well as altered media osmolarity. Therefore, it is important to replace the astrocyte medium with an adequate volume of differentiation medium (usually 1 mL/well of a 24-well plate). Additionally, the transfection of plasmid DNA is an easy and more accessible approach compared to viral transduction, which requires an approved safety level 2 cell culture room. However, transfection rate and reprograming efficiency are lower compared to viral-mediated delivery of the reprogramming factors. Therefore, transfection can be used as a fast method to test the reprogramming potential of new candidate reprogramming factors or to screen pools of factors. Regarding neuronal maturation, reprogrammed cells usually become electrophysiologically active at around 3 weeks. Though not required, treating the cells with small molecules increases both survival as well as maturation of the reprogrammed cells, leading to a higher density of induced neurons and a more mature morphology.

Although the described method to isolate and culture astrocytes is robust and reliable, a few aspects need to be considered. First, while conventional methods based on mechanical dissociation of tissue yield an overall higher number of cells in culture per tissue dissected40, a MAC-sorted approach requires the dissection of tissue from six to eight pups to isolate an adequate number of cells for subsequent experiments. Furthermore, the isolation of astrocytes is based on the expression of the ATPase Na+/K+ transporting subunit Beta2 protein (Atp1b2), recognized by the antibody ACSA-241. In principle, astrocytes not expressing Atp1b2 would be lost in the preparation, therefore causing a bias in the preparation. Although we cannot exclude that this is the case, our analysis of MACS flow-through revealed that few cells in the negative fraction were immunoreactive for the astroglia markers Sox9, suggesting the high efficiency of MAC-sorting protocol. A second caveat regarding Atp1b2 is related to its expression. Atp1b2 is specifically expressed by astrocytes at postnatal stage, while in the mouse adult brain other cell types express it, in particular myelinating oligodendrocytes and ependymal cells27. Therefore, a careful dissection of the area of interest and a myelin removal step is required to isolate astrocytes from adult brains.

Compared to other methods for isolating astrocytes, the MACS-based approach ensures high purity of the cultures (>90% of Sox9+ cells) and provides a standardized procedure to isolate astrocytes from different regions of the CNS. This is particularly important when comparing cultures from different CNS regions, as the culture purity obtained by classical mechanical dissociation can vary remarkably (>80% GFAP+/DAPI from cortical gray matter, ~50% GFAP+/DAPI from spinal cord)15,29. A standardized protocol reduces such variability and provides a common starting point for in vitro reprogramming experiments. This allows, for instance, to systematically compare the molecular identity of astrocytes from different regions28,29 and to investigate the impact of the developmental origin on the reprogramming efficiency and the subtype identity of the induced neurons.

In summary, in vitro direct neuronal reprogramming of optimized cultures of astrocytes is a very powerful approach to unravel universal as well as region-specific molecular mechanisms of astrocyte-to-neuron conversion, providing essential information to design better and more effective strategies for in vivo direct conversion of resident CNS astrocytes.

Subscription Required. Please recommend JoVE to your librarian.

Disclosures

The authors declare no conflicts of interest.

Acknowledgments

We would like to thank Ines Mühlhahn for cloning the constructs for reprogramming, Paulina Chlebik for viral production, and Magdalena Götz and Judith Fischer-Sternjak for comments on the manuscript.

Materials

Name Company Catalog Number Comments
0.05% Trypsin/EDTA Life Technologies 25300054
4', 6-Diamidino-2-phenyindole, dilactate (DAPI) Sigma-Aldrich D9564
anti-mouse IgG1 Alexa 647 Thermo Fisher A21240
anti-Mouse IgG1 Biotin Southernbiotech Cat# 1070-08; RRID: AB_2794413
anti-mouse IgG2b Alexa 488 Thermo Fisher A21121
anti-rabbit Alexa 546 Thermo Fisher A11010
Aqua Poly/Mount Polysciences Cat# 18606-20
B27 Supplement Life Technologies 17504044
BDNF Peprotech 450-02
bFGF Life Technologies 13256029
Bovine Serum Albumine (BSA) Sigma-Aldrich Cat# A9418
cAMP Sigma Aldrich D0260
C-Tubes Miltenyi Biotec 130-093-237
DMEM/F12 Life Technologies 21331020
Dorsomorphin Sigma Aldrich P5499
EGF Life Technologies PHG0311
Fetal Bovine Serum PAN Biotech P30-3302
Forskolin Sigma Aldrich F6886
GDNF Peprotech 450-10
gentleMACS Octo Dissociator Miltenyi Biotec 130-096-427
GFAP Dako Cat# Z0334; RRID: AB_100013482
Glucose Sigma Aldrich G8769
GlutaMax Life Technologies 35050038
HBSS Life Technologies 14025050
Hepes Life Technologies 15630056
Lipofectamine 2000 (Transfection reagent) Thermo Fisher Cat# 11668019
MACS SmartStrainer 70µm Miltenyi Biotec 130-098-462
MiniMACS Seperator Miltenyi Biotec 130-042-102
Mouse anti-ACSA-2 MicroBeat Kit  Miltenyi Biotec 130-097-678
Mouse IgG1 anti-Synaptophysin 1 Synaptic Systems Cat# 101 011 RRID:AB_887824)
Mouse IgG2b anti-Tuj-1 (βIII-tub) Sigma Aldrich T8660
MS columns Miltenyi Biotec 130-042-201
N2 Supplement Life Technologies 17502048
Neural Tissue Dissociation Kit  Miltenyi Biotec 130-092-628
NT3 Peprotech 450-03
octoMACS Separator Miltenyi Biotec 130-042-109
OptiMEM – GlutaMAX (serum-reduced medium) Thermo Fisher Cat# 51985-026
Penicillin/Streptomycin Life Technologies 15140122
Poly-D-Lysine Sigma Aldrich P1149
Rabbit anti-RFP Rockland Cat# 600-401-379; RRID:AB_2209751
Rabbit anti-Sox9 Sigma-Aldrich Cat# AB5535; RRID:AB_2239761
Streptavidin Alexa 405 Thermo Fisher Cat# S32351
Triton X-100 Sigma-Aldrich Cat# T9284

DOWNLOAD MATERIALS LIST

References

  1. Johnson, T. S., et al. Spatial cell type composition in normal and Alzheimers human brains is revealed using integrated mouse and human single cell RNA sequencing. Scientific Reports. 10, (1), 18014 (2020).
  2. Lake, B. B., et al. Neuronal subtypes and diversity revealed by single-nucleus RNA sequencing of the human brain. Science. 352, (6293), 1586-1590 (2016).
  3. Mayer, C., et al. Developmental diversification of cortical inhibitory interneurons. Nature. 555, (7697), 457-462 (2018).
  4. Nowakowski, T. J., et al. Spatiotemporal gene expression trajectories reveal developmental hierarchies of the human cortex. Science. 358, (6368), 1318-1323 (2017).
  5. Sagner, A., Briscoe, J. Establishing neuronal diversity in the spinal cord: a time and a place. Development. 146, (22), (2019).
  6. Zeisel, A., et al. Molecular architecture of the mouse nervous system. Cell. 174, (4), 999-1014 (2018).
  7. Iismaa, S. E., et al. Comparative regenerative mechanisms across different mammalian tissues. NPJ Regenerative Medicine. 3, 6 (2018).
  8. Lange, C., Brand, M. Vertebrate brain regeneration - a community effort of fate-restricted precursor cell types. Current Opinion in Genetics & Development. 64, 101-108 (2020).
  9. Poss, K. D. Advances in understanding tissue regenerative capacity and mechanisms in animals. Nature Reviews Genetics. 11, (10), 710-722 (2010).
  10. Grade, S., Gotz, M. Neuronal replacement therapy: previous achievements and challenges ahead. NPJ Regenerative Medicine. 2, 29 (2017).
  11. Barker, R. A., Gotz, M., Parmar, M. New approaches for brain repair-from rescue to reprogramming. Nature. 557, (7705), 329-334 (2018).
  12. Bocchi, R., Masserdotti, G., Gotz, M. Direct neuronal reprogramming: Fast forward from new concepts toward therapeutic approaches. Neuron. 110, (3), 366-393 (2022).
  13. Di Tullio, A., et al. CCAAT/enhancer binding protein alpha (C/EBP(alpha))-induced transdifferentiation of pre-B cells into macrophages involves no overt retrodifferentiation. Proceedings of the National Academy of Sciences of the United States of America. 108, (41), 17016-17021 (2011).
  14. Fishman, V. S., et al. Cell divisions are not essential for the direct conversion of fibroblasts into neuronal cells. Cell Cycle. 14, (8), 1188-1196 (2015).
  15. Heinrich, C., et al. Directing astroglia from the cerebral cortex into subtype specific functional neurons. PLoS Biology. 8, (5), 1000373 (2010).
  16. Treutlein, B., et al. Dissecting direct reprogramming from fibroblast to neuron using single-cell RNA-seq. Nature. 534, (7607), 391-395 (2016).
  17. Tapscott, S. J., et al. MyoD1: a nuclear phosphoprotein requiring a Myc homology region to convert fibroblasts to myoblasts. Science. 242, (4877), 405-411 (1988).
  18. Taylor, S. M., Jones, P. A. Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine. Cell. 17, (4), 771-779 (1979).
  19. Berninger, B., et al. Functional properties of neurons derived from in vitro reprogrammed postnatal astroglia. Journal of Neuroscience. 27, (32), 8654-8664 (2007).
  20. Marro, S., et al. Direct lineage conversion of terminally differentiated hepatocytes to functional neurons. Cell Stem Cell. 9, (4), 374-382 (2011).
  21. Vierbuchen, T., et al. Direct conversion of fibroblasts to functional neurons by defined factors. Nature. 463, (7284), 1035-1041 (2010).
  22. Bass, N. H., Hess, H. H., Pope, A., Thalheimer, C. Quantitative cytoarchitectonic distribution of neurons, glia, and DNa in rat cerebral cortex. The Journal of Comparative Neurology. 143, (4), 481-490 (1971).
  23. Yoon, H., Walters, G., Paulsen, A. R., Scarisbrick, I. A. Astrocyte heterogeneity across the brain and spinal cord occurs developmentally, in adulthood and in response to demyelination. PLoS One. 12, (7), 0180697 (2017).
  24. Taverna, E., Gotz, M., Huttner, W. B. The cell biology of neurogenesis: toward an understanding of the development and evolution of the neocortex. Annual Review of Cell and Developmental Biology. 30, 465-502 (2014).
  25. Batiuk, M. Y., et al. Identification of region-specific astrocyte subtypes at single cell resolution. Nature Communication. 11, (1), 1220 (2020).
  26. Boisvert, M. M., Erikson, G. A., Shokhirev, M. N., Allen, N. J. The aging astrocyte transcriptome from multiple regions of the mouse brain. Cell Reports. 22, (1), 269-285 (2018).
  27. Ohlig, S., et al. Molecular diversity of diencephalic astrocytes reveals adult astrogenesis regulated by Smad4. The EMBO Journal. 40, (21), 107532 (2021).
  28. Herrero-Navarro, A., et al. Astrocytes and neurons share region-specific transcriptional signatures that confer regional identity to neuronal reprogramming. Science Advances. 7, (15), (2021).
  29. Kempf, J., et al. Heterogeneity of neurons reprogrammed from spinal cord astrocytes by the proneural factors Ascl1 and Neurogenin2. Cell Reports. 36, (3), 109409 (2021).
  30. Mattugini, N., et al. Inducing Different Neuronal Subtypes from Astrocytes in the Injured Mouse Cerebral Cortex. Neuron. 103, (6), 1086-1095 (2019).
  31. Heins, N., et al. Glial cells generate neurons: the role of the transcription factor Pax6. Nature Neuroscience. 5, (4), 308-315 (2002).
  32. Masserdotti, G., et al. Transcriptional mechanisms of proneural factors and REST in regulating neuronal reprogramming of astrocytes. Cell Stem Cell. 17, (1), 74-88 (2015).
  33. Rao, Z., et al. Molecular mechanisms underlying Ascl1-mediated astrocyte-to-neuron conversion. Stem Cell Reports. 16, (3), 534-547 (2021).
  34. Gascon, S., et al. Identification and successful negotiation of a metabolic checkpoint in direct neuronal reprogramming. Cell Stem Cell. 18, (3), 396-409 (2016).
  35. Russo, G. L., et al. CRISPR-mediated induction of neuron-enriched mitochondrial proteins boosts direct glia-to-neuron conversion. Cell Stem Cell. 28, (3), 524-534 (2021).
  36. Guo, S., et al. Nonstochastic reprogramming from a privileged somatic cell state. Cell. 156, (4), 649-662 (2014).
  37. Hu, X., et al. Region-restrict astrocytes exhibit heterogeneous susceptibility to neuronal reprogramming. Stem Cell Reports. 12, (2), 290-304 (2019).
  38. Ge, W. P., Miyawaki, A., Gage, F. H., Jan, Y. N., Jan, L. Y. Local generation of glia is a major astrocyte source in postnatal cortex. Nature. 484, (7394), 376-380 (2012).
  39. Price, J. D., et al. The Ink4a/Arf locus is a barrier to direct neuronal transdifferentiation. The Journal of Neuroscience. 34, (37), 12560-12567 (2014).
  40. Heinrich, C., et al. Generation of subtype-specific neurons from postnatal astroglia of the mouse cerebral cortex. Nature Protocols. 6, (2), 214-228 (2011).
  41. Batiuk, M. Y., et al. An immunoaffinity-based method for isolating ultrapure adult astrocytes based on ATP1B2 targeting by the ACSA-2 antibody. The Journal of Biological Chemistry. 292, (21), 8874-8891 (2017).
This article has been published
Video Coming Soon
PDF DOI DOWNLOAD MATERIALS LIST

Cite this Article

Hersbach, B. A., Simon, T., Masserdotti, G. Isolation and Direct Neuronal Reprogramming of Mouse Astrocytes. J. Vis. Exp. (185), e64175, doi:10.3791/64175 (2022).More

Hersbach, B. A., Simon, T., Masserdotti, G. Isolation and Direct Neuronal Reprogramming of Mouse Astrocytes. J. Vis. Exp. (185), e64175, doi:10.3791/64175 (2022).

Less
Copy Citation Download Citation Reprints and Permissions
View Video

Get cutting-edge science videos from JoVE sent straight to your inbox every month.

Waiting X
Simple Hit Counter